{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:22:45Z","timestamp":1782544965095,"version":"3.54.5"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.seizure.2014.08.006","type":"journal-article","created":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T14:22:19Z","timestamp":1409062939000},"page":"127-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Withholding the choice of sodium valproate to young women with generalised epilepsy: Are we causing more harm than good?"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8732-8188","authenticated-orcid":false,"given":"Tom B.","family":"Mole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Appleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Marson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2014.08.006_bib0005","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2014.08.006_bib0010","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2011-300376","article-title":"KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy","volume":"84","author":"Trinka","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.seizure.2014.08.006_bib0015","series-title":"Patient and clinician summaries: guidelines on women with epilepsy and pregnancy","author":"American Academy of Neurology","year":"2009"},{"key":"10.1016\/j.seizure.2014.08.006_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/2042098611433192","article-title":"Antiepileptic drugs in women with epilepsy during pregnancy","volume":"3","author":"Gedzelman","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.seizure.2014.08.006_bib0025","series-title":"The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Nice clinical guideline 137","author":"NICE","year":"2012"},{"key":"10.1016\/j.seizure.2014.08.006_bib0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2014.08.006_bib0035","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2014.08.006_bib0040","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2014.08.006_bib0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-1211(00)00124-8","article-title":"Assessing risk to benefit ratio in antiepileptic drug therapy","volume":"41","author":"Perucca","year":"2000","journal-title":"Epilepsy Res"},{"issue":"98\u2013101","key":"10.1016\/j.seizure.2014.08.006_bib0050","first-page":"106","article-title":"The consequences of uncontrolled epilepsy","volume":"9","author":"Sperling","year":"2004","journal-title":"CNS Spectr"},{"key":"10.1016\/j.seizure.2014.08.006_bib0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1059-1311(97)80049-0","article-title":"Managing the teenager with epilepsy: paediatric to adult care","volume":"6","author":"Appleton","year":"1997","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.08.006_bib0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1515\/jpme.1979.7.1.3","article-title":"Fetal heart rate during a maternal grand mal epileptic seizure","volume":"7","author":"Teramo","year":"1979","journal-title":"J Perinat Med"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131114002349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131114002349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:44:38Z","timestamp":1761011078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131114002349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":12,"alternative-id":["S1059131114002349"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2014.08.006","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Withholding the choice of sodium valproate to young women with generalised epilepsy: Are we causing more harm than good?","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2014.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}